4th Quarter - Termination

THE PAUL LAXALT GROUP for THE ROGOSIN INSTITUTE

Firm
Client
Income
$30,000
Expenses
—
Terminated
Dec 31, 2018

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 25, 2019 $30,000 Replaced
4th Quarter - Termination (this page) Apr 22, 2019 $30,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Legislation and regulations relating to Medicare policies that impact care provided to patients with kidney disease.

LobbyistCovered position, as disclosed
TOM LORANGER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Monitor issues concerning improvements in medical research and treatment of kidney disease. Dialysis PATIENTS Demonstration Act of 2017 - HR 4143 and S 2065 The Chronic Kidney Disease Improvement in Research and Treatment Act of 2017 - HR 2644 and S 1980

LobbyistCovered position, as disclosed
TOM LORANGER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2644 (115th), H.R. 4143 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.